References
- Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 13–21.
- Kaplan RS, Wiemik PH. Neurotoxicity of antineoplastic drugs. Sem Oncol 1982; 9: 103–30.
- Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxi-city. Ann Pharmacother 1993; 27: 1519–25.
- McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228–44.
- Verschraegen C, Conrad CA, Hong WK. Subacute encephalo-pathic toxicity of cisplatin. Lung Cancer 1995; 13: 305–9.
- Gorman DJ, Kefford R, Stuart-Harris R. Focal encephalo-pathy after cisplatin therapy. Med J Aust 1989; 150: 399–401.
- Schweitzer VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103: 1–52.
- Walker EM Jr, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990; 10: 323–54.
- Lyass O, Lossos A, Hubert A, et al. Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 1998; 9: 100–4.
- Kondo K, Fujiwara M, Murase M, et al. Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: case report and review of the literature. Jpn J Clin Oncol 1996; 26: 234–6.
- Cairncross G, Swinnen L, Bayer R, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-oncol 2000; 2: 114–9.
- Hiesiger EM, Green SB, Shapiro WR, et al. Results of a randomized trial comparing intra-arterial cisplatin and intra-venous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group Trial 8420A. J Neurooncol 1995; 25: 143–54.
- Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999; 5: 501–6.
- McKeage MJ, Hsu T, Screnci D, et al. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001; 85: 1219–25.
- Meijer C, de Vries EG, Marmiroli P, et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuro-pathy. Neurotoxicology 1999; 20: 883–7.
- Park SA, Park HJ, Lee BI, et al. Bc1-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 2001; 93: 18–26.
- Park SA, Choi KS, Bang JH, et al. Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J Neurochem 2000; 75: 946–53.
- Abayomi O. Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncol 2002; 41: 346–51.
- Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339–41.
- Kumano T, Mutoh T, Nakagawa H, Kuriyama M. HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, trk, and morphological differentiation with fatal outcome in PC12 cells. Brain Res 2000; 859: 169–72.
- Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31: 971–97.
- Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47–8.